Several multitargeted TKIs, such as lestaurtinib, sunitinib, sorafenib, and midostaurin, have activity against FLT3 and have been investigated in patients with FLT3-ITD-mutated AML [31, 58–61]. This evidence concerns the gene FLT3 and acute myeloid leukemia.